Prospective, Dose-Escalating, Investigator Initiated Trial to Evaluate the Safety and Efficacy of ZM-01 in 3-18 Year-old Male Subjects With X-linked Retinoschisis
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Incidence of adverse events and serious adverse events
研究概览
简要总结
This trial is meant to evaluate the safety and efficacy of ZM-01 of X-linked retinoschisis. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
详细描述
X-linked retinoschisis (XLRS) is a rare, inherited retinal disease caused by mutations in the RS1 gene. Individuals affected by XLRS often experience progressive visual impairment from a young age, potentially leading to legal blindness. There is currently no established clinical treatment available. We developed an innovative adeno-associated virus (AAV)-based gene therapy for individuals with XLRS. Six to nine subjects with XLRS received a single unilateral intravitreal injection of ZM-01 at ascending doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 18 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects who meet all of the following criteria will be enrolled into the study
- •Diagnosis of X-linked retinoschisis consistent with the presence of RS1 gene mutation
- •Male, aged between 3 and 18 years old, in overall good health except for XLRS condition
- •Capable of undergoing visual and retinal function assessment.
- •The visual acuity of the study eye not better than: 0.4 (68 ETDRS letters equivalent)
- •No carbonic anhydrase inhibitors have been used at present and for 3 months before treatment
- •Laboratory tests meet the following criteria:
- •Hemoglobin ≥ 11.0 g/dL
- •White blood cell counts ranged from 3,300 to 12,000 cells /mm³;
- •Platelet count 125,000-550,000 /mm³;
- •Alanine aminotransferase (ALT) is not higher than 1.5 times the upper limit of the normal range of laboratory tests;
- •Serum creatinine was no higher than 1.1 times the upper limit of the normal range for laboratory tests;
- •Prothrombin time (PT) ≤14.5 seconds and partial thromboplastin time (PTT) ≤ 36.0 seconds.
- •Willing to discontinue aspirin, aspirin-containing products, and any other medications that may alter clotting function at least 7 days before dosing.
- •Be able to understand and sign informed consent.
排除标准
- •Subjects who meet any of the following exclusion criteria before enrollment were excluded from the study
- •Previously received any AAV gene therapy
- •The following mutations in RS1 gene: R141H, C59S or C223S
- •Pre-existing eye conditions that cause severe vision loss or increase the risk of intravitreal injections (e.g., advanced glaucoma, uveitis, or severe retinal detachment)
- •Ocular diseases in which there is opacity of the lens, cornea, or other media, hindering adequate observation and examination of the retina
- •Use anticoagulant or antiplatelet drugs within 7 days before dosing
- •Use any experimental drug within 3 months prior to registration
- •Presented any situation that causes the investigator to believe the subject might not adhere to the study protocol or that participation might pose an unacceptable risk to the subject
研究组 & 干预措施
group 1
IVT administration of a single low dose ZM-01 injection
干预措施: ZM-01-L (Drug)
group 2
IVT administration of a single high dose ZM-01 injection
干预措施: ZM-01-H (Drug)
结局指标
主要结局
Incidence of adverse events and serious adverse events
时间窗: baseline to day 7, month 1, 2
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment. A serious adverse event (SAE) is any untoward medical occurrence at any dose that leading to the following: Results in death; Life-threatening, refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe; Significant or permanent disability/incapacity, where disability refers to a serious disruption and damage of a person's ability to perform normal life functions; Requires inpatient hospitalization or prolongation of existing hospitalization; Congenital anomaly or birth defect; Other medically important events.
Change in best corrected visual acuity (BCVA)
时间窗: baseline to day 7, month 1, 2
BCVA of both eyes will be assessed using the early treatment of diabetic retinopathy study (ETDRS) chart or tumbling "E" chart. This approach was chosen to facilitate visual acuity testing in children who cannot recognize letters, which was more appropriate for this study.
次要结局
- Incidence of adverse events and serious adverse events(baseline to month 3, 4, 6, 9, 12)
- Change in Quality of Life(baseline to month 9, 12)
- Change in best corrected visual acuity (BCVA)(baseline to month 3, 4, 6, 9, 12)
- Change in visual field(baseline to month 1, 2, 3, 4, 6, 9, 12)
- Change in electrophysiology result(baseline to month 1, 2, 3, 4, 6, 9, 12)
- Anti-AAV neutralizing antibody titer, Anti-RS1 neutralizing antibody titer(baseline to day 1, 7 and month 1, 2)
- Change in the retina cavity assessed by macular OCT(baseline to day 7, month 1, 2, 3, 4, 6, 9, 12)